will require constant innovation

resistant to vancomycin and now linezolid illustrates the urgent need for novel antibiotic design strategies.

Written byPeter Moore
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

While enterococci are always quick to devise mechanisms for developing resistance to novel antibiotics, staphylococci seem to take longer. The differential pace of the development of resistance is fortunate in that enterococci have a tendency to be less virulent than staphylococci, but it only delays the inevitable — sooner or later staphylococci catch up.

Cases of methicillin resistant Staphylococcus aureus (MRSA) first arose in the 1980s, plaguing hospital wards and more recently moving out to attack people living in the community. Latest UK statistics show a 2% increase in reports of MRSA between 1999 and 2000.

The problem did not really initially cause widespread concern because it was thought the glycopeptide vancomycin could cope. But in May 1996 this assumption came under threat with the first reported case of S. aureus resistant to vancomycin. This first patient was in Japan, and it took a couple of years before one showed ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies